Q1 EPS Estimates for Bio-Techne Decreased by Leerink Partnrs

Key Points

• Leerink Partners has reduced their Q1 2026 earnings per share estimate for Bio-Techne Corp from $0.35 to $0.34, while the consensus estimate for the full year is $1.67 per share.
• Price targets and ratings for the stock vary, with some analysts upgrading Bio-Techne to a "strong buy" and a price target of $70.00, while others maintain a "sell" rating.
• Bio-Techne reported a quarterly dividend of $0.08 per share, reflecting a 0.5% dividend yield and a payout ratio of 69.57%.

Bio-Techne Corp (NASDAQ:TECH - Free Report) - Stock analysts at Leerink Partnrs lowered their Q1 2026 earnings per share estimates for Bio-Techne in a research note issued to investors on Monday, October 13th. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will earn $0.34 per share for the quarter, down from their prior forecast of $0.35. The consensus estimate for Bio-Techne's current full-year earnings is $1.67 per share. Leerink Partnrs also issued estimates for Bio-Techne's Q3 2026 earnings at $0.48 EPS, Q1 2027 earnings at $0.39 EPS and FY2027 earnings at $1.97 EPS.

A number of other brokerages also recently issued reports on TECH. Stephens upgraded Bio-Techne to a "strong-buy" rating and set a $65.00 price target on the stock in a research report on Tuesday, July 22nd. Weiss Ratings reiterated a "sell (d+)" rating on shares of Bio-Techne in a research report on Wednesday, October 8th. TD Cowen increased their price target on Bio-Techne from $65.00 to $70.00 and gave the stock a "buy" rating in a research report on Tuesday. Zacks Research upgraded Bio-Techne from a "strong sell" rating to a "hold" rating in a research report on Monday, October 6th. Finally, Cowen reiterated a "buy" rating on shares of Bio-Techne in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Bio-Techne has a consensus rating of "Moderate Buy" and a consensus target price of $70.58.

Bio-Techne Stock Down 0.6%

Shares of TECH opened at $59.27 on Wednesday. The company has a market capitalization of $9.23 billion, a price-to-earnings ratio of 128.85, a PEG ratio of 3.80 and a beta of 1.48. The stock's 50-day moving average price is $54.65 and its 200-day moving average price is $52.51. The company has a quick ratio of 2.38, a current ratio of 3.46 and a debt-to-equity ratio of 0.18. Bio-Techne has a 52 week low of $46.01 and a 52 week high of $80.80.

Bio-Techne (NASDAQ:TECH - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $0.53 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.03. Bio-Techne had a return on equity of 13.43% and a net margin of 6.02%.The firm had revenue of $316.96 million for the quarter, compared to the consensus estimate of $315.14 million. During the same quarter in the prior year, the business earned $0.49 earnings per share. The company's revenue was up 3.6% compared to the same quarter last year.

Bio-Techne Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Monday, August 18th were issued a dividend of $0.08 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.5%. Bio-Techne's dividend payout ratio is presently 69.57%.

Institutional Investors Weigh In On Bio-Techne

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD lifted its position in Bio-Techne by 6.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 11,375,279 shares of the biotechnology company's stock worth $666,933,000 after buying an additional 721,012 shares in the last quarter. Select Equity Group L.P. lifted its position in Bio-Techne by 129.8% during the first quarter. Select Equity Group L.P. now owns 5,366,003 shares of the biotechnology company's stock worth $314,609,000 after buying an additional 3,030,644 shares in the last quarter. Invesco Ltd. lifted its position in Bio-Techne by 9.7% during the first quarter. Invesco Ltd. now owns 4,190,115 shares of the biotechnology company's stock worth $245,666,000 after buying an additional 369,651 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in Bio-Techne by 18.5% during the first quarter. Massachusetts Financial Services Co. MA now owns 3,025,409 shares of the biotechnology company's stock worth $177,380,000 after buying an additional 472,847 shares in the last quarter. Finally, Champlain Investment Partners LLC lifted its position in Bio-Techne by 8.9% during the second quarter. Champlain Investment Partners LLC now owns 2,665,684 shares of the biotechnology company's stock worth $137,149,000 after buying an additional 217,362 shares in the last quarter. Institutional investors and hedge funds own 98.95% of the company's stock.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.